Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

BACKGROUND: Flavopiridol is a protein-bound, cytotoxic, cyclin dependent kinase inhibitor. A phase II trial of flavopiridol followed by ara-C and mitoxantrone with flavopiridol given by 1-h bolus for adults with newly-diagnosed, poor-risk acute myelogenous leukemia yielded 67% complete remission wit...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Karp, Judith E., Garrett-Mayer, Elizabeth, Estey, Elihu H., Rudek, Michelle A., Smith, B. Douglas, Greer, Jacqueline M., Drye, D. Michelle, Mackey, Karen, Dorcy, Kathleen Shannon, Gore, Steven D., Levis, Mark J., McDevitt, Michael A., Carraway, Hetty E., Pratz, Keith W., Gladstone, Douglas E., Showel, Margaret M., Othus, Megan, Doyle, L. Austin, Wright, John J., Pagel, John M.
Formato: Artigo
Idioma:Inglês
Publicado: Ferrata Storti Foundation 2012
Assuntos:
Original Articles and Brief Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3487449/
https://ncbi.nlm.nih.gov/pubmed/22733022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.062539
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares